ELSEVIER

Clinica Chimica Acta 292 (2000) 191–192

www.elsevier.com/locate/clinchim

Author index

Volume 292 (2000)

Abe, A., see Yamada, S. **292**, 187
Akbay, A., Bozbaş, A., İşgör, Y., Yavuz, Y., Elgün, S., Serum dipeptidylpeptidase activity and tissue polypeptide specific antigen in patients with advanced cirrhosis: preliminary results **292**, 181
Alimonti, A., Petrucci, F., Laurenti, F., Papoff, P., Caroli, S., Reference values for selected trace elements in serum of term newborns from the urban area of Rome **292**, 163
Angelitti, A.G., see Lippa, S. **292**, 81

Barchfeld, S., see Smirnov, A.V. **292**, 1
Beck, T., see Podebrad, F. **292**, 93
Böhles, H., see Podebrad, F. **292**, 93
Bondanini, F., see Lippa, S. **292**, 81
Bozbaş, A., see Akbay, A. **292**, 181
Brandsnes, Ø., see Tøn, H. **292**, 41
Brough, T., see Yeo, K.-T.J. **292**, 13

Cabrera, C.O., see Menéndez, G.R. **292**, 139
Callà, C., see Lippa, S. **292**, 81
Caroli, S., see Alimonti, A. **292**, 163
Ciccariello, M., see Lippa, S. **292**, 81
Cogliatti, S.B., see Korte, W. **292**, 149
Colacicco, L., see Lippa, S. **292**, 81

Dale, S., see Tøn, H. **292**, 41
Dewitte, K., Stöckl, D., Van de Velde, M., Thienpont, L.M., Evaluation of intrinsic and routine quality of serum total magnesium measurement **292**, 55
Diamandis, E.P., see Scorilas, A. **292**, 127
Dunne, F., see Hartland, A.J. **292**, 175

Elgün, S., see Akbay, A. **292**, 181

Fitzmaurice, T.F., see Yeo, K.-T.J. **292**, 13

Gilvarg, C., see Stewart, J.D. **292**, 107
Goossens, F.J., see Schatteman, K.A. **292**, 25
Gozzo, M.L., see Lippa, S. **292**, 81
Gregorakis, A.K., see Scorilas, A. **292**, 127

Hartland, A.J., Smith, J.M., Dunne, F., Correcting serum fructosamine concentration for total protein or albumin concentration is not appropriate during Asian pregnancy **292**, 175
Heil, M., see Podebrad, F. **292**, 93
Hendriks, D.F., see Schatteman, K.A. **292**, 25
Henne, S., see Smirnov, A.V. **292**, 1
Hoffmann, G.F., see Mayatepek, E. **292**, 155
Holtlund, J., see Tøn, H. **292**, 41

Inano, K., see Miida, T. **292**, 69
Inoue, K., see Yamada, S. **292**, 187
İşgör, Y., see Akbay, A. **292**, 181
Iyama, S., see Yamanishi, H. **292**, 117

Jayne, J.E., see Yeo, K.-T.J. **292**, 13
Johne, B., see Tøn, H. **292**, 41
Jung, K., see Korte, W. **292**, 149

Kashiwa, T., see Miida, T. **292**, 69
Korte, W., Cogliatti, S.B., Jung, K., Riesen, W., Mild renal dysfunction is sufficient to induce erythropoietin deficiency in patients with unexplained anaemia **292**, 149
Kubo, N., see Yamada, S. **292**, 187
Kubono, K., see Yamada, S. **292**, 187

Lange, P., see Smirnov, A.V. **292**, 1
Laurenti, F., see Alimonti, A. **292**, 163

PII: S0009-8981(00)00206-0

Li, Y., see Yeo, K.-T.J. **292**, 13
Lippa, S., Colacicco, L., Bondanini, F., Callà, C., Gozzo, M.L., Ciccariello, M., Angelitti, A.G., Plasma levels of coenzyme Q_{10}, vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications **292**, 81

Mäder, M., see Smirnov, A.V. **292**, 1
Mayatepek, E., Zelezny, R., Hoffmann, G.F., Analysis of leukotrienes in cerebrospinal fluid of a reference population and patients with inborn errors of metabolism: further evidence for a pathognomonic profile in LTC_4-synthesis deficiency **292**, 155
Menéndez, G.R., Cabrera, C.O., Selection of an optimal combination of decision criteria for the internal quality control in an automatic analyzer **292**, 139
Miida, T., Ozaki, K., Murakami, T., Kashiwa, T., Yamadera, T., Tsuda, T., Inano, K., Okada, M., Preβ1-high-density lipoprotein (preβ1-HDL) concentration can change with low-density lipoprotein-cholesterol (LDL-C) concentration independent of cholesteryl ester transfer protein (CETP) **292**, 69
Morishita, R., see Yamada, S. **292**, 187
Mosandl, A., see Podebrad, F. **292**, 93
Murakami, T., see Miida, T. **292**, 69

Nau, R., see Smirnov, A.V. **292**, 1

Ogihara, T., see Yamada, S. **292**, 187
Okada, M., see Miida, T. **292**, 69
Olgemöller, U., see Smirnov, A.V. **292**, 1
Ozaki, K., see Miida, T. **292**, 69

Papoff, P., see Alimonti, A. **292**, 163
Petrucci, F., see Alimonti, A. **292**, 163
Podebrad, F., Heil, M., Beck, T., Mosandl, A., Sewell, A.C., Böhles, H., Stereodifferentiation of 3-hydroxyisobutyric- and 3-aminoisobutyric acid in human urine by enantioselective multidimensional capillary gas chromatography–mass spectrometry **292**, 93

Quinn-Hall, K.S., see Yeo, K.-T.J. **292**, 13

Riesen, W., see Korte, W. **292**, 149

Sakurabayashi, I., see Yamada, S. **292**, 187
Scharpé, S.S., see Schatteman, K.A. **292**, 25
Schatteman, K.A., Goossens, F.J., Scharpé, S.S., Hendriks, D.F., Proteolytic activation of purified human procarboxypeptidase U **292**, 25
Schjønsby, H., see Tøn, H. **292**, 41
Scorilas, A., Yu, H., Soosaipillai, A.R., Gregorakis, A.K., Diamandis, E.P., Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy **292**, 127
Sewell, A.C., see Podebrad, F. **292**, 93
Skuibina, E., see Tøn, H. **292**, 41
Smirnov, A.V., Tumani, H., Henne, S., Barchfeld, S., Olgemöller, U., Wiltfang, J., Lange, P., Mäder, M., Nau, R., Glutamine synthetase in experimental meningitis: increased ratio of the subunits 3 and 2 may indicate enhanced activity **292**, 1
Smith, J.M., see Hartland, A.J. **292**, 175
Soosaipillai, A.R., see Scorilas, A. **292**, 127
Stewart, J.D., Gilvarg, C., Determination of serum procarboxypeptidase A concentrations in healthy human adults **292**, 107
Stöckl, D., see Dewitte, K. **292**, 55
Storm, C.A., see Yeo, K.-T.J. **292**, 13

Thienpont, L.M., see Dewitte, K. **292**, 55
Tøn, H., Brandsnes, Ø., Dale, S., Holtlund, J., Skuibina, E., Schjønsby, H., Johne, B., Improved assay for fecal calprotectin **292**, 41
Tsuda, T., see Miida, T. **292**, 69
Tumani, H., see Smirnov, A.V. **292**, 1

Van de Velde, M., see Dewitte, K. **292**, 55

Wiltfang, J., see Smirnov, A.V. **292**, 1

Yamada, S., Inoue, K., Morishita, R., Ogihara, T., Kubono, K., Kubo, N., Abe, A., Sakurabayashi, I., Erratum to "A new Lp(a) assay that is unaffected by apo(a) size polymorphism". [Clinca Chimica Acta 287 (1999) 29–43] **292**, 187
Yamadera, T., see Miida, T. **292**, 69
Yamaguchi, Y., see Yamanishi, H. **292**, 117
Yamanishi, H., Iyama, S., Yamaguchi, Y., Yanagihara, T., The effect of reaction temperature for nephelometric assays for rheumatoid factor **292**, 117
Yanagihara, T., see Yamanishi, H. **292**, 117
Yavuz, Y., see Akbay, A. **292**, 181
Yeo, K.-T.J., Storm, C.A., Li, Y., Jayne, J.E., Brough, T., Quinn-Hall, K.S., Fitzmaurice, T.F., Performance of the enhanced Abbott AxSYM Cardiac Troponin I reagent in patients with heterophilic antibodies **292**, 13
Yu, H., see Scorilas, A. **292**, 127

Zelezny, R., see Mayatepek, E. **292**, 155

ELSEVIER

Clinica Chimica Acta 292 (2000) 193–195

www.elsevier.com/locate/clinchim

Subject index

Volume 292 (2000)

3-Aminoisobutyric acid; Enantioselective multidimensional gas chromatography–mass spectrometry; Methyl chloroformate derivatization; Inherited metabolic disease; 3-Hydroxyisobutyric acid; Methylmalonic semialdehyde dehydrogenase deficiency **292**, 93

Anemia; Renal insufficiency; Erythropoietin; Myelodysplasia **292**, 149

Apolipoprotein AI; Reverse cholesterol transport; HDL subfraction; hypercholesterolemia **292**, 69

Apoptosis; Two-dimensional electrophoresis; Meningitis; *Streptococcus pneumoniae*; Glutamine synthetase (EC 6.3.1.2) **292**, 1

Asian pregnancy; Serum fructosamine concentration **292**, 175

Calprotectin; Feces; ELISA **292**, 41

Carboxypeptidase; Fibrinolysis; Plasminogen **292**, 25

Cardiac troponin I; Heterophilic antibody **292**, 13

Cerebrospinal fluid; Inborn errors of metabolism; Leukotrienes; Leukotriene C_4-synthesis deficiency **292**, 155

Coenzyme Q_{10}; Vitamin E; Kidney failure; Lipid peroxidation; Hemodialysis treatment **292**, 81

Differential diagnosis of prostate cancer from benign prostatic hyperplasia; Prostate specific antigen; Free prostate specific antigen; Tumor markers; Prostate cancer relapse **292**, 127

Dipeptidylpeptidase IV; Liver cirrhosis; Tissue polypeptide specific antigen; Serum; Human **292**, 181

ELISA; Calprotectin; Feces **292**, 41

Enantioselective multidimensional gas chromatography–mass spectrometry; Methyl chloroformate derivatization; Inherited metabolic disease; 3-Aminoisobutyric acid; 3-Hydroxyisobutyric acid; Methylmalonic semialdehyde dehydrogenase deficiency **292**, 93

Erythropoietin; Anemia; Renal insufficiency; Myelodysplasia **292**, 149

Feces; Calprotectin; ELISA **292**, 41

Fibrinolysis; Carboxypeptidase; Plasminogen **292**, 25

Free prostate specific antigen; Prostate specific antigen; Differential diagnosis of prostate cancer from benign prostatic hyperplasia; Tumor markers; Prostate cancer relapse **292**, 127

Glutamine synthetase (EC 6.3.1.2); Meningitis; *Streptococcus pneumoniae*; Apoptosis; Two-dimensional electrophoresis **292**, 1

PII: S0009-8981(00)00207-2

HDL subfraction; Reverse cholesterol transport; Apolipoprotein AI; hypercholesterolemia **292**, 69

Hemodialysis treatment; Coenzyme Q_{10}; Vitamin E; Kidney failure; Lipid peroxidation **292**, 81

Heterophilic antibody; Cardiac troponin I **292**, 13

Human; Liver cirrhosis; Tissue polypeptide specific antigen; Dipeptidylpeptidase IV; Serum **292**, 181

3-Hydroxyisobutyric acid; Enantioselective multidimensional gas chromatography–mass spectrometry; Methyl chloroformate derivatization; Inherited metabolic disease; 3-Aminoisobutyric acid; Methylmalonic semialdehyde dehydrogenase deficiency **292**, 93

Hypercholesterolemia; Reverse cholesterol transport; Apolipoprotein AI; HDL subfraction **292**, 69

Inborn errors of metabolism; Cerebrospinal fluid; Leukotrienes; Leukotriene C_4-synthesis deficiency **292**, 155

Inductively coupled plasma mass spectrometry; Trace elements reference values; Serum analysis; Newborns **292**, 163

Inherited metabolic disease; Enantioselective multidimensional gas chromatography–mass spectrometry; Methyl chloroformate derivatization; 3-Aminoisobutyric acid; 3-Hydroxyisobutyric acid; Methylmalonic semialdehyde dehydrogenase deficiency **292**, 93

Intrinsic quality; Total magnesium; Routine quality; Method comparison **292**, 55

Kidney failure; Coenzyme Q_{10}; Vitamin E; Lipid peroxidation; Hemodialysis treatment **292**, 81

Leukotriene C_4-synthesis deficiency; Cerebrospinal fluid; Inborn errors of metabolism; Leukotrienes **292**, 155

Leukotrienes; Cerebrospinal fluid; Inborn errors of metabolism; Leukotriene C_4-synthesis deficiency **292**, 155

Lipid peroxidation; Coenzyme Q_{10}; Vitamin E; Kidney failure; Hemodialysis treatment **292**, 81

Liver cirrhosis; Tissue polypeptide specific antigen; Dipeptidylpeptidase IV; Serum; Human **292**, 181

Meningitis; *Streptococcus pneumoniae*; Glutamine synthetase (EC 6.3.1.2); Apoptosis; Two-dimensional electrophoresis **292**, 1

Method comparison; Total magnesium; Intrinsic quality; Routine quality **292**, 55

Methyl chloroformate derivatization; Enantioselective multidimensional gas chromatography–mass spectrometry; Inherited metabolic disease; 3-Aminoisobutyric acid; 3-Hydroxyisobutyric acid; Methylmalonic semialdehyde dehydrogenase deficiency **292**, 93

Methylmalonic semialdehyde dehydrogenase deficiency; Enantioselective multidimensional gas chromatography–mass spectrometry; Methyl chloroformate derivatization; Inherited metabolic disease; 3-Aminoisobutyric acid; 3-Hydroxyisobutyric acid **292**, 93

Myelodysplasia; Anemia; Renal insufficiency; Erythropoietin **292**, 149

Newborns; Trace elements reference values; Serum analysis; Inductively coupled plasma mass spectrometry **292**, 163

Plasminogen; Carboxypeptidase; Fibrinolysis **292**, 25

Prostate cancer relapse; Prostate specific antigen; Free prostate specific antigen; Differential diagnosis of prostate cancer from benign prostatic hyperplasia; Tumor markers **292**, 127

Prostate specific antigen; Free prostate specific antigen; Differential diagnosis of prostate cancer from benign prostatic hyperplasia; Tumor markers; Prostate cancer relapse **292**, 127

Renal insufficiency; Anemia; Erythropoietin; Myelodysplasia **292**, 149

Reverse cholesterol transport; Apolipoprotein AI; HDL subfraction; hypercholesterolemia **292**, 69

Routine quality; Total magnesium; Intrinsic quality; Method comparison **292**, 55

Serum analysis; Trace elements reference values; Newborns; Inductively coupled plasma mass spectrometry **292**, 163

Serum fructosamine concentration; Asian pregnancy **292**, 175

Serum; Liver cirrhosis; Tissue polypeptide specific antigen; Dipeptidylpeptidase IV; Human **292**, 181

Streptococcus pneumoniae; Meningitis; Glutamine synthetase (EC 6.3.1.2); Apoptosis; Two-dimensional electrophoresis **292**, 1

Tissue polypeptide specific antigen; Liver cirrhosis; Dipeptidylpeptidase IV; Serum; Human **292**, 181

Total magnesium; Intrinsic quality; Routine quality; Method comparison **292**, 55

Trace elements reference values; Serum analysis; Newborns; Inductively coupled plasma mass spectrometry **292**, 163

Tumor markers; Prostate specific antigen; Free prostate specific antigen; Differential diagnosis of prostate cancer from benign prostatic hyperplasia; Prostate cancer relapse **292**, 127

Two-dimensional electrophoresis; Apoptosis; Meningitis; *Streptococcus pneumoniae*; Glutamine synthetase (EC 6.3.1.2) **292**, 1

Vitamin E; Coenzyme Q_{10}; Kidney failure; Lipid peroxidation; Hemodialysis treatment **292**, 81